Can-Fite BioPharma Ltd.

As of June 30, 2024, Can-Fite BioPharma Ltd. carries a market capitalization of 5.68B, placing it among publicly traded companies globally. Its enterprise value stands at 3.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Can-Fite BioPharma Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of June 30, 2024, Can-Fite BioPharma Ltd. has 557,242.00 shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Can-Fite BioPharma Ltd. maintains a current ratio of 2.93, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024.

As of the close on October 22, 2026, Can-Fite BioPharma Ltd.'s stock has declined approximately 89.89% over the past 52 weeks. The 50-day moving average sits at 399.82, while the 200-day moving average is 594.94.

As of June 30, 2024, Can-Fite BioPharma Ltd. holds 1.78B in cash and equivalents against 21.41M in total debt, resulting in a net debt position of -1.77B. Total book value stands at 930.94M, with working capital of 1.44B providing operational flexibility.

Can-Fite BioPharma Ltd.'s most recent stock split took place on January 5, 2026 with a 3000:1 split ratio.